Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neutropenia Risk Factors
Data on neutropenia risk factors reported by researchers at University of Tokyo
April 16th, 2007
A report, "A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study," is newly published data in Annals of Oncology. "Late-onset neutropenia (LON) has been reported following rituximab-containing chemotherapy. Its incidence and risk factors, however, have not been extensively studied. We retrospectively reviewed the medical records of 107 patients treated with rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphomas and identified cases with LON as defined by the neutrophil count of <or=1.0 x 10(9)/l without an apparent cause after...
Source: Hematology Week (2007-04-16)
|
